Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will discuss the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlight Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
Alzheimer’s disease has traditionally been viewed as a condition driven by a single protein, such as amyloid beta. However, emerging evidence suggests that multiple neurotoxic proteins—including amyloid beta, tau, alpha-synuclein, and TDP-43—contribute to disease progression. Annovis’ buntanetap is designed to inhibit the translation of these proteins through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients.
The presentation at Fierce Biotech Week is significant because it underscores a paradigm shift in Alzheimer’s research. If buntanetap proves successful in its Phase 3 trial, it could validate the multi-protein approach and offer a new therapeutic option for millions of patients worldwide. The announcement also reinforces Annovis’ position as a leader in neurodegenerative disease research.
For more information, the full press release can be accessed at https://ibn.fm/kZ2Z4. Investors seeking the latest news and updates regarding ANVS can visit the company’s newsroom at https://ibn.fm/ANVS.
